Now showing items 1-4 of 4

    • EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication. 

      Luteijn, JM; Morris, JK; Garne, E; Given, J; de Jong-van den Berg, L; Addor, M-C; Bakker, M; Barisic, I; Gatt, M; Klungsoyr, K (2016-10)
      AIMS: Information about medication safety in pregnancy is inadequate. We aimed to develop a signal detection methodology to routinely identify unusual associations between medications and congenital anomalies using data ...
    • EUROmediCAT signal detection: an evaluation of selected congenital anomaly-medication associations. 

      Given, JE; Loane, M; Luteijn, JM; Morris, JK; de Jong van den Berg, LTW; Garne, E; Addor, M-C; Barisic, I; de Walle, H; Gatt, M (2016-10)
      AIMS: To evaluate congenital anomaly (CA)-medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation. METHODS: Data from 15 EUROCAT registries ...
    • Prevalence of valproate syndrome in Europe from 2005 to 2014: A registry based multi-centre study. 

      Morris, JK; Garne, E; Loane, M; Addor, M-C; Barisic, I; Bianchi, F; Gatt, M; Lanzoni, M; Lynch, C; Mokoroa, O (2018-09)
      Women with epilepsy need to continue to take anticonvulsants during their pregnancies to prevent seizures from occurring. Since the 1980's, it has been known that the use of valproate (an anticonvulsant) in the first ...
    • Trends in congenital anomalies in Europe from 1980 to 2012. 

      Morris, JK; Springett, AL; Greenlees, R; Loane, M; Addor, M-C; Arriola, L; Barisic, I; Bergman, JEH; Csaky-Szunyogh, M; Dias, C (2018)
      BACKGROUND: Surveillance of congenital anomalies is important to identify potential teratogens. METHODS: This study analysed the prevalence of 61 congenital anomaly subgroups (excluding chromosomal) in 25 population-based ...